Shayan S Nazari

CONFLICT OF INTEREST STATEMENT Shayan S. Nazari, Yasmine Baca, Andrew Elliott, and Norm D. Smith are employees of Caris Life Sciences. Shuanzeng Wei is a member of the Caris Molecular Tumor Board. Daniel M. Geynisman reports advisory/consulting roles with Pfizer, Exelixis, AstraZeneca, Seattle Genetics/Astellas Pharma, Eisai, Merck, and Myovant Sciences; honoraria from Targeted Oncology; and institutional research funding from Merck, Astellas Pharma, Harpoon Therapeutics, Arvinas, and CG Oncology.

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

2. Materials and Methods 2.1. Cell Culture and Media The cell lines used included human breast carcinoma MDA-MB-231 bone (MDA-MB-231BO) cells originally described in [30] and obtained from Dr. Kandice Tanner, National Cancer Institute, as well as human oral squamous cell carcinoma SCC9 cells obtained from the Ashok Kulkarni laboratory, NIDCR, NIH. The cells were confirmed to be MDA-MB-231 and SCC-9 cells, respectively, by STR analysis (ATCC, Manassas, VA, USA).